- Coordinates
- PDB Format
- Method
- X-RAY DIFFRACTION 2.40 Å
- Oligo State
- monomer
- Ligands
- 2 x NAG- NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)
- 1 x NAG- NAG- BMA: beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose
- 1 x NAG- NAG- FUC: 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-[alpha-L-fucopyranose-(1-6)]2-acetamido-2-deoxy-beta-D-glucopyranose
- 2 x ZN: ZINC ION(Non-covalent)
- 1 x NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)
- 1 x NA: SODIUM ION(Non-functional Binders)
- 37 x IOD: IODIDE ION(Non-functional Binders)
IOD.9: 4 residues within 4Å:- Chain A: T.57, P.370, F.371, E.372
Ligand excluded by PLIPIOD.10: 4 residues within 4Å:- Chain A: N.154, K.156, N.157
- Ligands: NAG-NAG-FUC.4
Ligand excluded by PLIPIOD.11: 4 residues within 4Å:- Chain A: K.93, K.95, F.264, E.265
Ligand excluded by PLIPIOD.12: 5 residues within 4Å:- Chain A: K.156, S.189, T.190, R.193, Y.194
Ligand excluded by PLIPIOD.13: 5 residues within 4Å:- Chain A: Y.87, N.89, S.92, V.94, R.106
Ligand excluded by PLIPIOD.14: 6 residues within 4Å:- Chain A: F.254, P.255, N.256, A.288, A.292
- Ligands: NAG.7
Ligand excluded by PLIPIOD.15: 4 residues within 4Å:- Chain A: K.301, N.312, N.313, P.314
Ligand excluded by PLIPIOD.16: 4 residues within 4Å:- Chain A: Q.105, V.136, T.137
- Ligands: NAG-NAG-BMA.3
Ligand excluded by PLIPIOD.17: 1 residues within 4Å:- Chain A: K.93
Ligand excluded by PLIPIOD.18: 4 residues within 4Å:- Chain A: S.361, R.382, L.383, L.402
Ligand excluded by PLIPIOD.19: 3 residues within 4Å:- Chain A: E.158, T.159, R.162
Ligand excluded by PLIPIOD.20: 4 residues within 4Å:- Chain A: T.90, L.276, T.317, P.318
Ligand excluded by PLIPIOD.21: 1 residues within 4Å:- Chain A: T.240
Ligand excluded by PLIPIOD.22: 3 residues within 4Å:- Chain A: R.145
- Ligands: NAG-NAG-BMA.3, NAG-NAG-BMA.3
Ligand excluded by PLIPIOD.23: 2 residues within 4Å:- Chain A: T.91, S.92
Ligand excluded by PLIPIOD.24: 3 residues within 4Å:- Chain A: P.199, E.200, E.203
Ligand excluded by PLIPIOD.25: 4 residues within 4Å:- Chain A: S.146, R.147, W.171
- Ligands: NAG-NAG-BMA.3
Ligand excluded by PLIPIOD.26: 4 residues within 4Å:- Chain A: Y.98, H.99, Y.155
- Ligands: PC.46
Ligand excluded by PLIPIOD.27: 2 residues within 4Å:- Chain A: R.125, R.145
Ligand excluded by PLIPIOD.28: 4 residues within 4Å:- Chain A: L.276, P.277, L.282, P.318
Ligand excluded by PLIPIOD.29: 4 residues within 4Å:- Chain A: K.21, T.173, L.224, R.227
Ligand excluded by PLIPIOD.30: 4 residues within 4Å:- Chain A: Y.194, G.195, T.240, N.339
Ligand excluded by PLIPIOD.31: 3 residues within 4Å:- Chain A: R.363, A.364, H.403
Ligand excluded by PLIPIOD.32: 2 residues within 4Å:- Chain A: K.253, P.255
Ligand excluded by PLIPIOD.33: 4 residues within 4Å:- Chain A: N.154, Y.155, K.156, S.189
Ligand excluded by PLIPIOD.34: 4 residues within 4Å:- Chain A: M.63, Y.269, H.342, G.343
Ligand excluded by PLIPIOD.35: 3 residues within 4Å:- Ligands: NAG-NAG.1, NAG-NAG.2, NAG-NAG.2
Ligand excluded by PLIPIOD.36: 3 residues within 4Å:- Chain A: R.147
- Ligands: NAG-NAG-BMA.3, NAG-NAG-BMA.3
Ligand excluded by PLIPIOD.37: 2 residues within 4Å:- Chain A: P.97, A.100
Ligand excluded by PLIPIOD.38: 2 residues within 4Å:- Chain A: V.368, P.400
Ligand excluded by PLIPIOD.39: 2 residues within 4Å:- Chain A: A.396, T.397
Ligand excluded by PLIPIOD.40: 4 residues within 4Å:- Chain A: G.103, I.104, Q.105, R.106
Ligand excluded by PLIPIOD.41: 4 residues within 4Å:- Chain A: H.99, K.148, E.149, G.150
Ligand excluded by PLIPIOD.42: 2 residues within 4Å:- Chain A: K.75, N.79
Ligand excluded by PLIPIOD.43: 2 residues within 4Å:- Chain A: Y.214, E.217
Ligand excluded by PLIPIOD.44: 4 residues within 4Å:- Chain A: G.150, I.151, A.152
- Ligands: IOD.45
Ligand excluded by PLIPIOD.45: 4 residues within 4Å:- Chain A: G.150, A.152, H.153
- Ligands: IOD.44
Ligand excluded by PLIP- 1 x PC: PHOSPHOCHOLINE(Non-covalent)
PC.46: 15 residues within 4Å:- Chain A: D.28, T.64, N.85, Y.98, Y.155, Y.183, G.185, D.188, S.189, H.192, Y.269, H.342
- Ligands: ZN.5, ZN.6, IOD.26
8 PLIP interactions:8 interactions with chain A- Hydrogen bonds: A:T.64, A:N.85, A:Y.269
- Salt bridges: A:D.28, A:D.188, A:H.192, A:H.342
- pi-Cation interactions: A:Y.155
- Links
- RCSB PDBe PDBe-KB PDBj PDBsum CATH PLIP
- Citation
- Gorelik, A. et al., Crystal structure of the human alkaline sphingomyelinase provides insights into substrate recognition. J. Biol. Chem. (2017)
- Release Date
- 2017-03-22
- Peptides
- Ectonucleotide pyrophosphatase/phosphodiesterase family member 7: A
- SMTL:PDB
- SMTL Chain Id:
PDB Chain Id:A
A
- Coordinates
- PDB Format
- Method
- X-RAY DIFFRACTION 2.40 Å
- Oligo State
- monomer
- Ligands
- 2 x NAG- NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)
- 1 x NAG- NAG- BMA: beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose
- 1 x NAG- NAG- FUC: 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-[alpha-L-fucopyranose-(1-6)]2-acetamido-2-deoxy-beta-D-glucopyranose
- 2 x ZN: ZINC ION(Non-covalent)
- 1 x NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)
- 1 x NA: SODIUM ION(Non-functional Binders)
- 37 x IOD: IODIDE ION(Non-functional Binders)
- 1 x PC: PHOSPHOCHOLINE(Non-covalent)
- Links
- RCSB PDBe PDBe-KB PDBj PDBsum CATH PLIP
- Citation
- Gorelik, A. et al., Crystal structure of the human alkaline sphingomyelinase provides insights into substrate recognition. J. Biol. Chem. (2017)
- Release Date
- 2017-03-22
- Peptides
- Ectonucleotide pyrophosphatase/phosphodiesterase family member 7: A
- SMTL:PDB
- SMTL Chain Id:
PDB Chain Id:A
A